Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Long Noncoding RNAs in Acute Myeloid Leukemia: Functional Characterization and Clinical Relevance.

Gourvest M, Brousset P, Bousquet M.

Cancers (Basel). 2019 Oct 24;11(11). pii: E1638. doi: 10.3390/cancers11111638. Review.

2.

MIAmS: microsatellite instability detection on NGS amplicons data.

Escudié F, Van Goethem C, Grand D, Vendrell J, Vigier A, Brousset P, Evrard SM, Solassol J, Selves J.

Bioinformatics. 2019 Oct 24. pii: btz797. doi: 10.1093/bioinformatics/btz797. [Epub ahead of print]

PMID:
31647522
3.

[New entities and new tools in hematopathology as proposed by the 2016 WHO classification: Case 7].

Laurent C, Brousset P.

Ann Pathol. 2019 Sep;39(5):335-338. doi: 10.1016/j.annpat.2019.05.004. Epub 2019 Aug 9. French. No abstract available.

PMID:
31405614
4.

[New entities and new tools in hematopathology as proposed by the 2016 WHO classification: Case 3].

Brousset P.

Ann Pathol. 2019 Sep;39(5):318-320. doi: 10.1016/j.annpat.2019.07.003. Epub 2019 Aug 9. French. No abstract available.

PMID:
31405613
5.

[New entities and new tools in hematopathology as proposed by the 2016 WHO classification: Case 6].

Laurent C, Brousset P.

Ann Pathol. 2019 Sep;39(5):331-334. doi: 10.1016/j.annpat.2019.05.003. Epub 2019 Aug 9. French. No abstract available.

PMID:
31405612
6.

[New entities and new tools in hematopathology as proposed by the 2016 WHO classification: Case 1].

Brousset P.

Ann Pathol. 2019 Sep;39(5):309-312. doi: 10.1016/j.annpat.2019.07.004. Epub 2019 Aug 9. French. No abstract available.

PMID:
31405611
7.

A transgenic mouse model reproduces human hereditary systemic amyloidosis.

Chabert M, Rousset X, Colombat M, Lacasa M, Kakanakou H, Bourderioux M, Brousset P, Burlet-Schiltz O, Liepnieks JJ, Kluve-Beckerman B, Lambert G, Châtelet FP, Benson MD, Kalopissis AD.

Kidney Int. 2019 Sep;96(3):628-641. doi: 10.1016/j.kint.2019.03.013. Epub 2019 Mar 28.

PMID:
31200944
8.

Proteomic evidence of specific IGKV1-8 association with cystic lung light chain deposition disease.

Camus M, Hirschi S, Prevot G, Chenard MP, Mal H, Stern M, Reynaud-Gaubert M, Gilhodes J, Burlet-Schiltz O, Brousset P, Colombat M.

Blood. 2019 Jun 27;133(26):2741-2744. doi: 10.1182/blood.2019898577. Epub 2019 Apr 9.

PMID:
30967366
9.

Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs.

Vendrell JA, Mazieres J, Senal R, Rouquette I, Quantin X, Pujol JL, Roch B, Bouidioua A, Godreuil S, Coyaud E, Brousset P, Solassol J.

Clin Cancer Res. 2019 Jul 15;25(14):4280-4289. doi: 10.1158/1078-0432.CCR-18-2683. Epub 2019 Apr 1.

PMID:
30936123
10.

Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.

Torossian A, Broin N, Frentzel J, Daugrois C, Gandarillas S, Saati TA, Lamant L, Brousset P, Giuriato S, Espinos E.

Haematologica. 2019 Jul;104(7):1428-1439. doi: 10.3324/haematol.2017.181966. Epub 2019 Jan 24.

11.

Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.

Péricart S, Tosolini M, Gravelle P, Rossi C, Traverse-Glehen A, Amara N, Franchet C, Martin E, Bezombes C, Laurent G, Brousset P, Fournié JJ, Laurent C.

Cancers (Basel). 2018 Oct 31;10(11). pii: E415. doi: 10.3390/cancers10110415.

12.

Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Evrard SM, Péricart S, Grand D, Amara N, Escudié F, Gilhodes J, Bories P, Traverse-Glehen A, Dubois R, Brousset P, Parrens M, Laurent C.

Haematologica. 2019 Apr;104(4):e154-e157. doi: 10.3324/haematol.2018.198572. Epub 2018 Oct 11. No abstract available.

13.

EBV infection determines the immune hallmarks of plasmablastic lymphoma.

Gravelle P, Péricart S, Tosolini M, Fabiani B, Coppo P, Amara N, Traverse-Gléhen A, Van Acker N, Brousset P, Fournie JJ, Laurent C.

Oncoimmunology. 2018 Jul 30;7(10):e1486950. doi: 10.1080/2162402X.2018.1486950. eCollection 2018.

14.

miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.

Hoareau-Aveilla C, Quelen C, Congras A, Caillet N, Labourdette D, Dozier C, Brousset P, Lamant L, Meggetto F.

Haematologica. 2019 Feb;104(2):347-359. doi: 10.3324/haematol.2018.195131. Epub 2018 Sep 27.

15.

PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.

Jamrog L, Chemin G, Fregona V, Coster L, Pasquet M, Oudinet C, Rouquié N, Prade N, Lagarde S, Cresson C, Hébrard S, Nguyen Huu NS, Bousquet M, Quelen C, Brousset P, Mancini SJC, Delabesse E, Khamlichi AA, Gerby B, Broccardo C.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10357-10362. doi: 10.1073/pnas.1721678115. Epub 2018 Sep 26.

16.

New insights into breast implant-associated anaplastic large cell lymphoma.

Laurent C, Haioun C, Brousset P, Gaulard P.

Curr Opin Oncol. 2018 Sep;30(5):292-300. doi: 10.1097/CCO.0000000000000476. Review.

PMID:
30096095
17.

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.

Menguy T, Briaux A, Jeunesse E, Giustiniani J, Calcei A, Guyon T, Mizrahi J, Haegel H, Duong V, Soler V, Brousset P, Bensussan A, Raymond Letron I, Le Bouteiller P.

Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2687-2698. doi: 10.1167/iovs.18-24024.

PMID:
29860455
18.

Prevalence of CD30 immunostaining in neoplastic mast cells: A retrospective immunohistochemical study.

Russano de Paiva Silva G, Tournier E, Sarian LO, Bulai-Livideanu C, Delsol G, Lamant L, Vassallo J, Brousset P, Laurent C.

Medicine (Baltimore). 2018 May;97(21):e10642. doi: 10.1097/MD.0000000000010642.

19.

Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells.

Congras A, Caillet N, Torossian N, Quelen C, Daugrois C, Brousset P, Lamant L, Meggetto F, Hoareau-Aveilla C.

Oncotarget. 2018 Feb 8;9(18):14539-14551. doi: 10.18632/oncotarget.24465. eCollection 2018 Mar 6.

20.

Expert central review in lymphoma diagnosis. Is there a need?

Laurent C, Gaulard P, Brousset P.

Oncotarget. 2017 Dec 17;8(70):114426-114427. doi: 10.18632/oncotarget.23357. eCollection 2017 Dec 29. No abstract available.

21.

18F-Fluorodeoxyglucose positron emission tomography computed tomography detection threshold in follicular lymphoma: A case report.

Péricart S, Martin-Blondel G, Franchet C, Hitzel A, Brousset P.

Medicine (Baltimore). 2017 Nov;96(47):e8705. doi: 10.1097/MD.0000000000008705.

22.

CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.

Xerri L, Adélaïde J, Popovici C, Garnier S, Guille A, Mescam-Mancini L, Laurent C, Brousset P, Coze C, Michel G, Chaffanet M, Bouabdallah R, Coso D, Bertucci F, Birnbaum D.

Am J Surg Pathol. 2018 Feb;42(2):150-159. doi: 10.1097/PAS.0000000000000989.

PMID:
29194093
23.

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.

Vendrell JA, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazières J, Costes V, Pujol JL, Brousset P, Rouquette I, Solassol J.

Sci Rep. 2017 Oct 2;7(1):12510. doi: 10.1038/s41598-017-12679-8.

24.

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.

De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C, Martelli MP, Falini B, Brousset P, Bousquet M.

Haematologica. 2017 Oct;102(10):1718-1726. doi: 10.3324/haematol.2017.171645. Epub 2017 Jul 4.

25.

Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.

Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P.

J Clin Oncol. 2017 Jun 20;35(18):2008-2017. doi: 10.1200/JCO.2016.71.2083. Epub 2017 May 1.

PMID:
28459613
26.

MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.

Ducassou S, Prouzet-Mauléon V, Deau MC, Brunet de la Grange P, Cardinaud B, Soueidan H, Quelen C, Brousset P, Pasquet JM, Moreau-Gaudry F, Arock M, Mahon FX, Lippert E.

J Pathol. 2017 Jul;242(3):347-357. doi: 10.1002/path.4908. Epub 2017 May 29.

PMID:
28418072
27.

High-throughput detection of clinically targetable alterations using next-generation sequencing.

Vendrell JA, Grand D, Rouquette I, Costes V, Icher S, Selves J, Larrieux M, Barbe A, Brousset P, Solassol J.

Oncotarget. 2017 Jun 20;8(25):40345-40358. doi: 10.18632/oncotarget.15875.

28.

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C.

Oncotarget. 2017 Jul 4;8(27):44960-44975. doi: 10.18632/oncotarget.16680. Review.

29.

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID.

Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. doi: 10.1158/1078-0432.CCR-16-2818. Epub 2017 Apr 5.

30.

Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement.

Gravelle P, Do C, Franchet C, Mueller S, Oberic L, Ysebaert L, Larocca LM, Hohaus S, Calmels MN, Frenois FX, Kridel R, Gascoyne RD, Laurent G, Brousset P, Valitutti S, Laurent C.

Oncoimmunology. 2016 Aug 24;5(10):e1224044. eCollection 2016.

31.

A case report of isolated lymphadenopathy revealing localized leishmanial lymphadenopathy in an asthenic 25-year-old man.

Hurlot Q, Fillaux J, Laurent C, Berry A, Hofman P, Marchou B, Delobel P, Brousset P, Martin-Blondel G.

Medicine (Baltimore). 2016 Jul;95(29):e3932. doi: 10.1097/MD.0000000000003932.

32.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

33.

Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.

Laurent C, Fabiani B, Do C, Tchernonog E, Cartron G, Gravelle P, Amara N, Malot S, Palisoc MM, Copie-Bergman C, Glehen AT, Copin MC, Brousset P, Pittaluga S, Jaffe ES, Coppo P.

Haematologica. 2016 Aug;101(8):976-84. doi: 10.3324/haematol.2016.141978. Epub 2016 May 12.

34.

PERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stress.

Philippe C, Dubrac A, Quelen C, Desquesnes A, Van Den Berghe L, Ségura C, Filleron T, Pyronnet S, Prats H, Brousset P, Touriol C.

Sci Signal. 2016 May 3;9(426):ra44. doi: 10.1126/scisignal.aaf2753.

PMID:
27141928
35.

Anti-CD8 (SP57) rabbit monoclonal antibody is a useful tool for detecting Toxoplasma gondii on formalin-fixed, paraffin-embedded tissue sections.

Manfredi L, Uro-Coste E, Brousset P.

Hum Pathol. 2016 Jun;52:197-8. doi: 10.1016/j.humpath.2015.09.047. Epub 2016 Mar 4. No abstract available.

PMID:
26980035
36.

Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.

Bousquet M, Noirot C, Accadbled F, Sales de Gauzy J, Castex MP, Brousset P, Gomez-Brouchet A.

Ann Oncol. 2016 Apr;27(4):738-44. doi: 10.1093/annonc/mdw009. Epub 2016 Jan 19.

PMID:
26787232
37.

Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.

Manfredi L, Meyer N, Tournier E, Grand D, Uro-Coste E, Rochaix P, Brousset P, Lamant L.

Acta Derm Venereol. 2016 Jun 15;96(5):630-4. doi: 10.2340/00015555-2326.

38.

Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.

Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L.

Ann Oncol. 2016 Feb;27(2):306-14. doi: 10.1093/annonc/mdv575. Epub 2015 Nov 23.

39.

Key contribution of eIF4H-mediated translational control in tumor promotion.

Vaysse C, Philippe C, Martineau Y, Quelen C, Hieblot C, Renaud C, Nicaise Y, Desquesnes A, Pannese M, Filleron T, Escourrou G, Lawson M, Rintoul RC, Delisle MB, Pyronnet S, Brousset P, Prats H, Touriol C.

Oncotarget. 2015 Nov 24;6(37):39924-40. doi: 10.18632/oncotarget.5442.

40.

Several immune escape patterns in non-Hodgkin's lymphomas.

Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, Brousset P, Bidaut A, Ycart B, Fournié JJ.

Oncoimmunology. 2015 Apr 2;4(8):e1026530. eCollection 2015 Aug.

41.

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.

Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau I, Lamant L, Meggetto F, Espinos E, Codogno P, Brousset P, Giuriato S.

Oncotarget. 2015 Oct 6;6(30):30149-64. doi: 10.18632/oncotarget.4999.

42.

Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Hoareau-Aveilla C, Valentin T, Daugrois C, Quelen C, Mitou G, Quentin S, Jia J, Spicuglia S, Ferrier P, Ceccon M, Giuriato S, Gambacorti-Passerini C, Brousset P, Lamant L, Meggetto F.

J Clin Invest. 2015 Sep;125(9):3505-18. doi: 10.1172/JCI78488. Epub 2015 Aug 10.

43.

RNA editing in acute myeloid leukaemia with normal karyotype.

Quelen C, Eloit Y, Noirot C, Bousquet M, Brousset P.

Br J Haematol. 2016 Jun;173(5):788-90. doi: 10.1111/bjh.13631. Epub 2015 Aug 7. No abstract available.

PMID:
26251186
44.

Prevalence of Common Non-Hodgkin Lymphomas and Subtypes of Hodgkin Lymphoma by Nodal Site of Involvement: A Systematic Retrospective Review of 938 Cases.

Laurent C, Do C, Gourraud PA, de Paiva GR, Valmary S, Brousset P.

Medicine (Baltimore). 2015 Jun;94(25):e987. doi: 10.1097/MD.0000000000000987.

45.

Cutaneous inflammatory myofibroblastic tumours can be anaplastic lymphoma kinase-positive: report of the first four cases.

Leguellec S, Tournier E, Karanian M, Brousset P, Mazereeuw J, Coindre JM, Lamant L.

Histopathology. 2016 Jan;68(2):297-302. doi: 10.1111/his.12759. Epub 2015 Aug 7.

PMID:
26100036
46.

Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia.

Berquet L, Valleron W, Grgurevic S, Quelen C, Zaki O, Quillet-Mary A, Davi F, Brousset P, Bousquet M, Ysebaert L.

Br J Haematol. 2016 Mar;172(5):819-23. doi: 10.1111/bjh.13544. Epub 2015 Jun 11. No abstract available.

PMID:
26095450
47.

Follicular variant of peripheral T cell lymphoma with mediastinal involvement in a child: a case report.

Delas A, Gaulard P, Plat G, Brousset P, Laurent C.

Virchows Arch. 2015 Mar;466(3):351-5. doi: 10.1007/s00428-015-1716-9. Epub 2015 Jan 22.

PMID:
25604350
48.

Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation.

McCormick SR, Higgins RR, Grutkoski PS, Bousquet M, Quelen C, Bartholomaus LM, Brousset P.

Br J Haematol. 2015 Apr;169(2):290-3. doi: 10.1111/bjh.13190. Epub 2014 Oct 15. No abstract available.

PMID:
25316507
49.

Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study.

Kirzin S, Marisa L, Guimbaud R, De Reynies A, Legrain M, Laurent-Puig P, Cordelier P, Pradère B, Bonnet D, Meggetto F, Portier G, Brousset P, Selves J.

PLoS One. 2014 Aug 1;9(8):e103159. doi: 10.1371/journal.pone.0103159. eCollection 2014.

50.

Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies.

Swerdlow SH, Jaffe ES, Brousset P, Chan JK, de Leval L, Gaulard P, Harris NL, Pileri S, Weiss LM; International Lymphoma Study Group.

Am J Surg Pathol. 2014 Oct;38(10):e60-71. doi: 10.1097/PAS.0000000000000295. Review.

Supplemental Content

Loading ...
Support Center